About Radiopharmaceuticals
Radiopharmaceuticals are pharmaceutical drugs having radioactive properties. The drugs can be used for therapeutic and diagnostic purposes. It is made up of radioisotope that bonds to an organic molecule. The radiopharmaceuticals find large application in the medical field due to their intrinsic properties. The radiopharmaceutical market is expected to benefit from the growing demand from the cancer market. Cancer is one of the major segments having a huge demand for radiopharmaceuticals for both therapeutic and diagnostic segments. Some of the other major segments finding the huge application of radiopharmaceuticals are neurology, cardiology, and thyroid disorder treatment.
Technavio’s analysts forecast the global radiopharmaceuticals market to grow at a CAGR of 9.02% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global radiopharmaceuticals market for 2017-2021. To calculate the market size, the report considers the sales of radiopharmaceuticals.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Radiopharmaceuticals Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bayer,
• Cardinal Health,
• GE Healthcare,
• Lantheus Medical Imaging
Other prominent vendors
• ABT Molecular Imaging
• Advanced Accelerator Applications
• Algeta
• Eczacibasi-Monrol Nuclear Products
• FUJIFILM Holdings
• Isologic Innovative Radiopharmaceuticals
• Nordion
• Piramal Imaging
• RadioMedix
• Triad Isotopes
Market driver
• Rising burden of the neurological disorders
• For a full, detailed list, view our report
Market challenge
• Shortage of radioisotopes
• For a full, detailed list, view our report
Market trend
• Partnerships for development of radiopharmaceuticals
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 06: Pipeline analysis
PART 07: Market segmentation by application
• Diagnostics
• Therapeutics
PART 08: Geographical segmentation
• Radiopharmaceuticals market in Americas
• Radiopharmaceutical market in EMEA
• Radiopharmaceuticals market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
• Market drivers
• Market challenges
PART 11: Market trends
• Partnerships for development of radiopharmaceuticals
• Production based on cyclotron
PART 12: Vendor landscape
PART 13: Key vendor analysis
• Bayer
• Cardinal Health
• GE Healthcare
• Lantheus Medical Imaging
• Other prominent members
PART 14: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Characteristics of radiopharmaceuticals
Exhibit 02: Factors affecting the development of new radiopharmaceutical
Exhibit 03: Applications of radiopharmaceuticals
Exhibit 04: Advantages and disadvantages of radiopharmaceuticals
Exhibit 05: Global radiopharmaceuticals market snapshot
Exhibit 06: Global radiopharmaceuticals market 2016-2021 ($ millions)
Exhibit 07: Opportunity analysis in global radiopharmaceuticals market
Exhibit 08: Five forces analysis
Exhibit 09: Key pipeline molecules by vendors
Exhibit 10: Key clinical trials
Exhibit 11: Segmentation of global radiopharmaceuticals market by application 2016
Exhibit 12: Segmentation of global radiopharmaceuticals market by application 2016 and 2021 (%)
Exhibit 13: Global radiopharmaceutical diagnostics market 2016-2021 ($ millions)
Exhibit 14: Diagnostic radiopharmaceuticals used in various clinical practices
Exhibit 15: Techniques of radiopharmaceutical imaging
Exhibit 16: Global radiopharmaceutical therapeutics market 2016-2021 ($ millions)
Exhibit 17: Commonly used radiopharmaceuticals for targeted radionuclide therapy
Exhibit 18: Treatment of tumors and cancers with radioisotopes
Exhibit 19: Segmentation of global radiopharmaceuticals market based on geography 2016 and 2021 (%)
Exhibit 20: Segmentation of global radiopharmaceuticals market revenue by geography 2016-2021 ($ millions)
Exhibit 21: Segmentation of global radiopharmaceuticals market share by geography 2016-2021 (%)
Exhibit 22: Market scenario in Americas
Exhibit 23: Radiopharmaceuticals market in Americas 2016-2021 ($ millions)
Exhibit 24: Radiopharmaceuticals market scenario in EMEA
Exhibit 25: Radiopharmaceuticals market in EMEA 2016-2021 ($ millions)
Exhibit 26: Radiopharmaceuticals market scenario in APAC
Exhibit 27: Radiopharmaceuticals market in APAC 2016-2021 ($ millions)
Exhibit 28: Functions of JRIA
Exhibit 29: Facts about the neurological disorders
Exhibit 30: Problems associated with the radiopharmaceutical drugs
Exhibit 31: Competitive structure analysis of the global pharmaceutical market 2016
Exhibit 32: Bayer: Key highlights
Exhibit 33: Bayer: Strength assessment
Exhibit 34: Bayer: Strategy assessment
Exhibit 35: Bayer: opportunity assessment
Exhibit 36: Cardinal Health: Key highlights
Exhibit 37: Cardinal Health: Strength assessment
Exhibit 38: Cardinal Health: Strategy assessment
Exhibit 39: Cardinal Health: Opportunity assessment
Exhibit 40: GE Healthcare: Key highlights
Exhibit 41: GE Healthcare: Strength assessment
Exhibit 42: GE Healthcare: Strategy assessment
Exhibit 43: GE Healthcare: Opportunity assessment
Exhibit 44: Lantheus Medical Imaging: Key highlights
Exhibit 45: Lantheus Medical Imaging: Strength assessment
Exhibit 46: Lantheus Medical Imaging: Strategy assessment
Exhibit 47: Lantheus Medical Imaging: Opportunity assessment
